A Phase Ib/II Clinical Study of GH21 Capsules Combined With Osimertinib Mesylate Tablets in Patients With NSCLC

Clinical trial NCT06306456 · RECRUITING

Trial details

NCT number: NCT06306456
Sponsor: Suzhou Genhouse Bio Co., Ltd.
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Non-Small Cell Lung Cancer With EGFR Mutation

Start date: 2024-03-05
Primary completion: 2025-12-31
Enrollment: 94

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.